» Articles » PMID: 23326756

Controversies in the Management and Followup of Differentiated Thyroid Cancer: Beyond the Guidelines

Overview
Journal J Thyroid Res
Publisher Wiley
Specialty Endocrinology
Date 2013 Jan 18
PMID 23326756
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer is among the most common endocrine malignancies. Genetic and environmental factors play an important role in the pathogenesis of differentiated thyroid cancer. Both have good prognosis but with frequent recurrences. Cancer staging is an essential prognostic part of cancer management. There are multiple controversies in the management and followup of differentiated thyroid cancer. Debate still exists with regard to the optimal surgical approach but trends toward a more conservative approach, such as lobectomy, are being more favored, especially in papillary thyroid cancer, of tumor sizes less than 4 cm, in the absence of other high-risk suggestive features. Survival of patients with well-differentiated thyroid cancer was adversely affected by lymph node metastases. Prophylactic central LN dissection did improve accuracy in staging and decrease postop TG level, but it had no effect on small-sized tumors. Conservative approach was more applied with regard to the need and dose of radioiodine given postoperatively. There have been several advancements in the management of radioiodine resistant advanced differentiated thyroid cancers. Appropriate followup is required based on risk stratification of patients postoperatively. Many studies are still ongoing in order to reach the optimal management and followup of differentiated thyroid cancer.

Citing Articles

The necessity of thyroid-stimulating hormone suppression therapy for low-risk differentiated thyroid carcinoma following hemithyroidectomy: A systematic review and meta-analysis.

Wang X, Ye Y, Amdulla M, Ren C, Liu Y, Ni S Heliyon. 2024; 10(23):e40574.

PMID: 39654735 PMC: 11626026. DOI: 10.1016/j.heliyon.2024.e40574.


Upregulation of miR-142 in papillary thyroid carcinoma tissues: a report based on in silico and in vitro analysis.

Valizadeh S, Zehtabi M, Feiziordaklou N, Akbarpour Z, Mahdi Khamaneh A, Raeisi M Mol Biol Res Commun. 2023; 11(3):133-141.

PMID: 36718241 PMC: 9661674. DOI: 10.22099/mbrc.2022.43947.1757.


Differentiated thyroid cancer: feasibility of loboisthmectomy in an endemic region.

Calo G, Erdas E, Medas F, Gordini L, Longheu A, Pisano G G Chir. 2016; 36(6):257-62.

PMID: 26888701 PMC: 4767372. DOI: 10.11138/gchir/2015.36.6.257.


Clinical impact of microscopic extrathyroidal extension in patients with papillary thyroid microcarcinoma treated with hemithyroidectomy.

Ahn D, Sohn J, Jeon J, Jeong J J Endocrinol Invest. 2014; 37(2):167-73.

PMID: 24497215 DOI: 10.1007/s40618-013-0025-x.

References
1.
Sugitani I, Fujimoto Y . Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab. 2010; 95(10):4576-83. DOI: 10.1210/jc.2010-0161. View

2.
Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso J, Al Ghuzlan A . Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab. 2009; 94(4):1162-7. DOI: 10.1210/jc.2008-1931. View

3.
Zafon C . TSH-suppressive treatment in differentiated thyroid cancer. A dogma under review. Endocrinol Nutr. 2011; 59(2):125-30. DOI: 10.1016/j.endonu.2011.10.002. View

4.
Farahati J, Reiners C, Stuschke M, Muller S, Stuben G, Sauerwein W . Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer. 1996; 77(1):172-80. DOI: 10.1002/(SICI)1097-0142(19960101)77:1<172::AID-CNCR28>3.0.CO;2-1. View

5.
Tsang R, Brierley J, Simpson W, Panzarella T, Gospodarowicz M, Sutcliffe S . The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998; 82(2):375-88. View